Navigation Links
New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
Date:9/20/2012

RIDGEFIELD, Conn., Sept. 20, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that data from 13 abstracts assessing the efficacy and safety of two of its investigational oncology compounds – afatinib and nintedanib – were selected for presentation at the ESMO 2012 Congress (European Society for Medical Oncology) in Vienna, Austria, September 28 – October 2, 2012.  These data represent Boehringer Ingelheim's commitment to further develop its oncology pipeline with the goal of bringing new treatment options to the oncology community.

Data will include results from Phase II and III studies of afatinib in various lung cancer treatment settings and patient groups as well as data on health-related quality of life and symptom control.  Data from Phase I studies of afatinib in advanced solid tumors will also be presented.  The nintedanib results are from Phase I studies in hepatocellular carcinoma and in combination with afatinib in advanced solid tumors.

"Boehringer Ingelheim is looking forward to sharing new results for our investigational oncology compounds with the global oncology community at ESMO," said Berthold Greifenberg, M.D., vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. "This is an exciting time for Boehringer Ingelheim as we continue to explore the potential of our growing oncology pipeline."

 

Data for Boehringer Ingelheim Investigational Oncology Compounds at ESMO 2012TitleLead Study AuthorAbstract DetailsAfatinib*LUX-Lung 3: Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in LUX-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed in EGFR mutation-positive lung cancer

James Chih-Hsin Yang,

MD, PhD

ESMO Abstract # 1252P
Date: Saturday, September 29
Time: 13:00 – 14:00 PM CESTPhase II trial of afatinib as a third-line treatme
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
2. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
3. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
4. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
5. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
8. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
9. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... managed with the use of special anti-vascular endothelial growth factor agents given by ... patients, currently does not have a scientific protocol for the many millions diagnosed ...
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... ENGLEWOOD, Colo. , Sept. 2, 2015 ... focused on developing treatments for urological and related conditions, ... of its planned private placement convertible note financing, raising ... two prior tranches totaling $3.175 million. ... stated, "Proceeds from this private placement are intended to ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. ... BeHEARD von 2015 bekanntgeben zu können. Hierbei handelt ... Institute. Biovista unterstützt mit seiner Möglichkeit ... Behandlung anderer Krankheiten als denen, für die ein ... und sein Team bei der Wylder Nation Foundation ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Plastics are everywhere in our modern world, largely due ... but lightweight and easily workable. One of their most ... than break when put under stress - is also ... "plastic flow", allows many plastics to change shape to ...
... U.S. Pharmacopeial (USP) Convention is pleased to announce that Matthew Heyman ... integration on December 1, 2008. , ... Rockville, Md. ... is pleased to announce that Matthew Heyman joined the organization ...
... new way of thinking in integrated imaging , ... the European Society of Nuclear Medicine meeting in October ... demand in a time when the current economical situation demands maximum ... reaches the United States as a pioneer, not only in hybrid ...
Cached Biology Technology:Fast molecular rearrangements hold key to plastic's toughness 2Fast molecular rearrangements hold key to plastic's toughness 3USP Names Matthew Heyman Vice President of External Affairs and Strategic Integration 2USP Names Matthew Heyman Vice President of External Affairs and Strategic Integration 3Imaging in Living Color with Siemens Molecular CT 2Imaging in Living Color with Siemens Molecular CT 3Imaging in Living Color with Siemens Molecular CT 4
(Date:8/18/2015)... PRINCETON, N.J. , Aug. 18, 2015 ... be a key contributor to the Submission ... hosted by IRISS, a non-profit forum. Dedicated to ... IRISS provides a neutral platform for industry, ... to share information and work towards a ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions , ... entire spectrum of clinical research, is proud to announce ... company,s comprehensive SaaS-based eClinical technology platform, has led the ... first two quarters of 2015.   Q2 2015 and ... quarters measured by contract value sold in the company,s ...
(Date:8/12/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that four of its fingerprint ID products, ... been named FIDO Certified™ by the Fast IDentity ... Synaptics, Natural ID™ fingerprint solutions are fully compliant ... standard and are interoperable among other products and ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... food in northern Ghana difficult enough. It doesn,t help that ... to power tractors for planting crops or to power grain ... seeds from some native trees may be able to help. ... to create biodiesel from the seeds of trees that are ...
... the Exxon Valdez oil spill devastated a vast stretch of ... be unable to effectively manage a large oil spill, according ... 20th anniversary of the Exxon Valdez spill approaches on March ... offshore oil development in the Arctic until technologies improve to ...
... of Illinois plant geneticist Stephen Moose has developed a corn ... that would make good silage, Moose said, due to a ... make it a good energy crop. The gene known ... giving corn seedlings a waxy coating that acts like a ...
Cached Biology News:K-State researchers work with university in Ghana to create biofuels from native tree seeds 2Arctic governments and industry still unprepared for oil spills 20 years after Exxon Valdez 2Arctic governments and industry still unprepared for oil spills 20 years after Exxon Valdez 3Doubling a gene in corn results in giant biomass 2
... Protein G bind specifically to Fc regions ... Protein G conjugates are commonly used as ... immunoglobulin subtypes from serum, hybridoma ascites fluids, ... These reagents are also commonly used to ...
... instrument engineered to match the speed of ... of research centers worldwide. It uses 1.5 ... ideally suited for high-speed temperature cycling due ... surface-area-to-volume ratio. ,By combining glass capillary tubes ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... LNA microarray slides for microRNA expression ... incorporate Exiqons unique Locked Nucleic Acid (LNA) ... mismatch discrimination for short microRNA (miRNA) targets. ... 1 g total RNA (no need for ...
Biology Products: